Clinical Trials Sponsored by Scientific Center EFiS LLC

Total 54 results

R-Pharm
Almedis; Scientific Center EFiS; ChromSystemsLab

Completed

Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1

Chronic Hepatitis c Genotype 1

Russian Federation
M.D. Anderson Cancer Center
Janssen Scientific Affairs, LLC

Recruiting

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation with Androgen Axis Suppression. a Phase III Multi-center Study for Men with Detectable PSA After Prostatectomy for Prostate Cancer.

Prostate Cancer | Prostatectomy | Androgen Axis Suppression

United States
M.D. Anderson Cancer Center
Janssen Scientific Affairs, LLC

Completed

Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center

Cancer | Pulmonary Embolism | Non-valvular Atrial Fibrillation | Deep-vein Thrombosis of the Lower and Upper Extremities

United States
Jonsson Comprehensive Cancer Center
Janssen Scientific Affairs, LLC

Recruiting

Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients with Prostate Cancer, HEATWAVE Trial (HEATWAVE)

Prostate Adenocarcinoma | Stage II Prostate Cancer AJCC V8 | Stage IIIA Prostate Cancer AJCC V8 | Stage IIIB Prostate Cancer AJCC V8

United States
M.D. Anderson Cancer Center
Janssen Scientific Affairs, LLC

Withdrawn

Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)

Lung Cancer, Nonsmall Cell, Stage I
M.D. Anderson Cancer Center
Janssen Scientific Affairs, LLC

Withdrawn

Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL)

Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
Memorial Sloan Kettering Cancer Center
Janssen Scientific Affairs, LLC

Active, not recruiting

Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis

Multiple Myeloma | AL Amyloidosis

United States
Memorial Sloan Kettering Cancer Center
Janssen Scientific Affairs, LLC

Completed

Short Course Daratumumab in Patients With Multiple Myeloma

Multiple Myeloma

United States
Memorial Sloan Kettering Cancer Center
Janssen Scientific Affairs, LLC

Recruiting

A Study of Health-Related Quality of Life in People with Multiple Myeloma Receiving Daratumumab or Lenalidomide

Multiple Myeloma

United States
Memorial Sloan Kettering Cancer Center
Janssen Scientific Affairs, LLC

Active, not recruiting

A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)

Metastatic Non Small Cell Lung Cancer | Recurrent Non Small Cell Lung Cancer

United States
Boston Medical Center
Janssen Scientific Affairs, LLC

Completed

Pharmacist-led Intervention on Adherence in Patients Undergoing Treatment With an Oral Oncology Medication (BSPAP)

Adherence, Medication

United States
Heart Center Research, LLC
Boston Scientific Corporation

Recruiting

Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts (DART-HA)

Heart Failure, Congestive

United States
University of Michigan Rogel Cancer Center
Janssen Scientific Affairs, LLC

Active, not recruiting

A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer (ASCLEPIuS)

Prostate Cancer

United States
University of Michigan Rogel Cancer Center
Janssen Scientific Affairs, LLC

Active, not recruiting

Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy

Multiple Myeloma

United States
M.D. Anderson Cancer Center
Ortho-McNeil Janssen Scientific Affairs, LLC

Terminated

Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients

Breast Cancer | Fatigue | Gastrointestinal Cancer

United States
Memorial Sloan Kettering Cancer Center
Janssen Scientific Affairs, LLC; Novartis Pharmaceuticals

Completed

A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma

Lymphoma | Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma

United States
University of Michigan Rogel Cancer Center
AstraZeneca; Janssen Scientific Affairs, LLC

Active, not recruiting

Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma

Sarcoma | Sarcoma Metastatic

United States
The Crofoot Research Center, Inc.
Janssen Scientific Affairs, LLC

Completed

Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART) (ReSTART)

HIV-1-infection

United States
Beth Israel Deaconess Medical Center
Janssen Scientific Affairs, LLC

Completed

Mechanisms of Weight Loss With SGLT2 Inhibition

Obesity | Overweight | Type 2 Diabetes

United States
University of Colorado, Denver
Janssen Scientific Affairs, LLC

Terminated

Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis

Hepatitis C

United States
Dana-Farber Cancer Institute
Janssen Scientific Affairs, LLC

Active, not recruiting

Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy

Prostate Cancer

United States
Dana-Farber Cancer Institute
Janssen Scientific Affairs, LLC

Terminated

Conventional ADT w/ or w/Out Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT

Prostate Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Janssen Scientific Affairs, LLC

Active, not recruiting

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States
Jennifer Woyach
Janssen Scientific Affairs, LLC

Completed

Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Monoclonal Gammopathy of Undetermined Significance | Myelodysplastic Syndrome | Aplastic Anemia | Symptomatic COVID-19 Infection Laboratory-Confirmed | Monoclonal B-Cell Lymphocytosis

United States
M.D. Anderson Cancer Center
Bristol-Myers Squibb; Pfizer; Janssen Scientific Affairs, LLC

Completed

Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center
Janssen Scientific Affairs, LLC; Xynomic Pharmaceuticals, Inc.

Active, not recruiting

Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma

Mantle Cell Lymphoma | Diffuse Large B-cell Lymphoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC; Janssen Scientific Affairs, LLC

Terminated

Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC; Janssen Scientific Affairs, LLC

Completed

Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers

Colorectal Cancer | Colon Cancer | Colorectal Carcinoma | Colon Disease

United States
R-Pharm International, LLC
Data Management 365; Federal State Budgetary Educational Institution for Higher... and other collaborators

Withdrawn

Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)

Adult-Onset Still's Disease | AOSD

Russian Federation
Psoriasis Treatment Center of Central New Jersey
Janssen Scientific Affairs, LLC

Completed

An Outcomes Study to Determine the Reasons Patients on Biologic Therapy Discontinue Treatment and Fail to Follow-up With Their Providers

Psoriasis

United States
Emory University
National Cancer Institute (NCI); Janssen Scientific Affairs, LLC

Terminated

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

Renal Failure | Plasma Cell Myeloma

United States
Stanford University
University of Colorado, Denver; Janssen Scientific Affairs, LLC

Withdrawn

Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated Toxicity (TMC114HIV2030)

HIV/AIDS

United States
Northwestern University
National Cancer Institute (NCI); Janssen Scientific Affairs, LLC

Active, not recruiting

Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma

Stage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell Lymphoma | Stage I Mantle Cell Lymphoma

United States
The University of Texas Health Science Center,...
Janssen Scientific Affairs, LLC

Withdrawn

Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer

Prostate Cancer

United States
Vanderbilt University
Ortho-McNeil Janssen Scientific Affairs, LLC

Completed

Does Risperidone Consta Reduce Relapse and Rehospitalization in Bipolar Disorder? (Consta)

Bipolar Disorder

United States
National Cancer Institute (NCI)
Janssen Scientific Affairs, LLC

Active, not recruiting

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma

Multiple Myeloma

United States
University of Washington
National Cancer Institute (NCI); Janssen Scientific Affairs, LLC

Completed

A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy

Stage III Prostate Adenocarcinoma AJCC v7 | Stage IV Prostate Adenocarcinoma AJCC v7 | Stage IV Prostate Cancer AJCC v7 | Stage III Prostate Cancer AJCC v7

United States
University of Washington
National Cancer Institute (NCI); Janssen Scientific Affairs, LLC

Terminated

Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance

Prostate Adenocarcinoma

United States
AIDS Malignancy Consortium
National Cancer Institute (NCI); Memorial Sloan Kettering Cancer Center; Janssen... and other collaborators

Active, not recruiting

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

Plasmablastic Lymphoma | Ann Arbor Stage I Diffuse Large B-Cell Lymphoma | Ann Arbor Stage II Diffuse Large B-Cell Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma

United States
The University of Texas Health Science Center at...
Janssen Scientific Affairs, LLC

Withdrawn

Effects of Canagliflozin on Intravascular Volume and Hemodynamics

Cardiovascular Diseases | Type2 Diabetes Mellitus

United States
Montefiore Medical Center
Icahn School of Medicine at Mount Sinai; Janssen Scientific Affairs, LLC

Recruiting

Social Determinants of Health, Medication Use, and Quality of Life in Inflammatory Bowel Disease

Inflammatory Bowel Diseases

United States
The University of Texas Health Science Center at...
Janssen Scientific Affairs, LLC

Completed

Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI); Janssen Scientific Affairs, LLC

Withdrawn

Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Recurrent Plasma Cell Myeloma

United States
OHSU Knight Cancer Institute
Janssen Scientific Affairs, LLC; Oregon Health and Science University

Active, not recruiting

Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer

Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Castration-Sensitive Prostate Carcinoma

United States
The University of Texas Health Science Center at...
Ortho-McNeil Janssen Scientific Affairs, LLC

Completed

Neuroimaging of the Effects of Concerta in the Treatment of ADHD

Attention Deficit Disorder With Hyperactivity

United States
The University of Texas Health Science Center at...
Ortho-McNeil Janssen Scientific Affairs, LLC

Completed

The Consta Club: A Demonstration Project for Setting up a Consta Club in a Community Mental Health Center

Schizophrenia | Schizoaffective

United States
Zaynudin Zaynudinov, MD, PhD
LLC IDS Borjomi

Completed

The Impact of a Regular Borjomi® Consumption on an Anaerobic Performance

Healthy

Russian Federation
Children's Hospital Medical Center, Cincinnati
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Janssen...

Recruiting

Precise Infliximab Exposure and Pharmacodynamic Control (REMODEL-CD)

Crohn Disease

United States
Sarcoma Alliance for Research through Collaboration
National Cancer Institute (NCI); Janssen Scientific Affairs, LLC; National Institutes...

Active, not recruiting

SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients (U01CA236220)

Ewing Sarcoma

United States
Memorial Sloan Kettering Cancer Center
University of California, Los Angeles; Ferring Pharmaceuticals; Wayne State University and other collaborators

Completed

3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy

Prostate Cancer

United States

Clinical Trials Sponsored by Scientific Center EFiS LLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations